Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

Summary by cancernetwork.com
The European Commission has approved encorafenib plus cetuximab and FOLFOX as the first BRAF-targeted regimen authorized in the EU for first-line BRAF V600E–mutant metastatic colorectal cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

cancernetwork.comcancernetwork.com

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

The European Commission has approved encorafenib plus cetuximab and FOLFOX as the first BRAF-targeted regimen authorized in the EU for first-line BRAF V600E–mutant metastatic colorectal cancer.

Read Full Article
pharmatimes.compharmatimes.com

Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC

Breakwater phase 3 data show significant gains in progression‑free survival

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

pharmatimes.com broke the news on Tuesday, June 23, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

France icon

France

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal